$CRVO
CervoMed Inc.
Nasdaq · Healthcare · Pharmaceutical Preparations · Boston, MA
CRVO chart
What traders are saying about $CRVO
Latest postsCervoMed Inc. news
- Form 4 CervoMed Inc: Matthew Winton (Chief Commercial and Business) For: 22 October By Investing.com
Investing.com South Africa ·
- Options covering 19,100 shares vest over 36 months for CervoMed (CRVO)'s clinical development EVP.
Stock Titan ·
- Options at $2.24 a share go to CervoMed (CRVO) executive Mark De Rosch.
Stock Titan ·
- With a $2.24 exercise price, CervoMed (CRVO) awards Matthew Winton 19,100 stock options.
Stock Titan ·
- CervoMed Inc. Estimates – NASDAQ:CRVO
TradingView ·
- CRVO News | CERVOMED INC (NASDAQ:CRVO)
ChartMill ·
- CervoMed Presents Initial Results of Phase 2a Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Showing Positive Effects on a Key Neurodegeneration Biomarker in Late-Breaking Oral Session at ISFTD 2026
Yahoo Finance ·
- CervoMed Announces Pharmacokinetic Results with New Neflamapimod Oral Tablet Formulation and Secures FDA Removal of Drug Exposure Limit
Yahoo Finance ·
- CervoMed to Participate in the 5th Annual ROTH Healthcare Opportunities Conference
Yahoo Finance ·
- CervoMed Announces Initial Results from the Phase 2a Clinical Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Have Been Accepted as a Late-Breaking Oral Session at ISFTD 2026
Yahoo Finance ·
- CervoMed to Participate in September Investor Conferences
Yahoo Finance ·
- CervoMed to Participate in Fireside Chat to Highlight Recent Progress in the Neflamapimod Clinical Development Program at the Canaccord Genuity 46th Annual Growth Conference
Yahoo Finance ·
CervoMed Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $4.0M | $9.7M | $7.1M | $0 |
| Net income | -$27.0M | -$16.3M | -$2.2M | -$5.8M |
| Diluted EPS | – | – | – | $2038891.00 |
| Total assets (year end) | $22.9M | $43.1M | $10.0M | $4.2M |
| Cash and equivalents (year end) | $8.2M | $9.0M | $7.8M | $4.1M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About CervoMed Inc.
- Ticker
- CRVO (Nasdaq)
- Industry
- Pharmaceutical Preparations
- Headquarters
- Boston, MA
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 1053691
- Former names
- Diffusion Pharmaceuticals Inc., RestorGenex Corp, Stratus Media Group, Inc
Frequently asked questions
What exchange is CervoMed Inc. listed on?
CervoMed Inc. trades on the Nasdaq under the ticker symbol CRVO.
What industry is CervoMed Inc. in?
CervoMed Inc. is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is CervoMed Inc. headquartered?
CervoMed Inc.'s business address on file with the SEC is in Boston, MA.
When does CervoMed Inc.'s fiscal year end?
CervoMed Inc.'s fiscal year ends on December 31.
How much revenue did CervoMed Inc. report?
CervoMed Inc. reported $4.0M in revenue for calendar year 2025, according to its SEC filings.